Hong Kong: Bioheart raises HK$442m from listing on HKEX

Shanghai-based Bioheart is a leading interventional cardiovascular device company, listed shares in December on the Hong Kong stock exchange. It issued a total of 23.937 million shares in a global offering at an issue price of HK$21.25, raising the company net proceeds of approximately HK$441.7m (US$56.7m). Around 90% of the net proceeds will be used…

You must be a HMI Subscriber to view this content.

Subscribe Now »